TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Dose Strengths of Selexipag in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key inclusion Criteria:~* Male subjects aged from 18 to 45 years (inclusive) at screening~* Signed informed consent form~* Body mass index (BMI) between 18.0 and 28.0 kg/m2 (inclusive) at screening~* Healthy on the basis of physical examination,cardiovascular assessments and laboratory tests~Key exclusion Criteria:~* Any contraindication to the study treatments~* History or clinical evidence of any disease or medical / surgical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study treatments~* Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sequence AB (Type: EXPERIMENTAL): Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2
- Sequence BA (Type: EXPERIMENTAL): Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Acute Migraine Headache in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or Females age 8-18 years~2. Girls 11 years or older must have a negative urine/serum pregnancy test.~3. Diagnosis of pediatric migrainous headache. The criteria for pediatric migraine headache based on the most recent ICHD criteria are listed below. The requirement of 5 attacks (A) will not be required for this study, this making the diagnosis migrainous headache. As described elsewhere in the protocol, this change is required to make the study applicable to ED patients who require treatment before five attacks have occurred.~Exclusion Criteria:~1. Evidence that headache is due to a secondary underlying disorder based on history or physical examination.~2. Pregnant or lactating females.~3. Any investigational drug use within 30 days.~4. Known to have a contraindication to metoclopramide or valproic acid such as pregnancy, liver disease, hematologic disease, or metabolic disease.~5. Have used metoclopramide (or other antidopaminergic medications) or valproic acid within two days of presentation.~6. Severe developmental disorders or mental retardation if insufficient information can be obtained to make a clear diagnosis of migraine or judge headache severity.~7. If patients re-present to the ED, they can not be re-enrolled.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Standard care including intravenous fluid, but no metoclopramide.
- Metoclopramide (Type: ACTIVE_COMPARATOR): Standard care including intravenous fluid PLUS metoclopramide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary dysmenorrhea~Exclusion Criteria:~* severe hepatopathy~* pregnant woman

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IKH-01 (Type: EXPERIMENTAL): ethinyl estradiol 0.035mg and norethisterone 1mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-acetylcysteine in the Treatment of PTSD and Addiction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 year old~* U.S. military Veteran, Reservist, or National Guard member~* DSM-IV diagnostic criteria for current (past 6 months) SUD and PTSD or subthreshold PTSD (i.e., met criteria for cluster B (re-experiencing) and either cluster C (avoidance) or D (hyperarousal), as well as duration of one month and clinically significant impairment)~* Score of \> 21 on the Mini-Mental State Exam (MMSE).~Exclusion Criteria:~* Unstable medical conditions~* Bipolar or psychotic disorders~* Seizures or asthma~* Prior treatment with NAC~* Suicidality~* Enrolled in ongoing PTSD treatment (pharmacotherapy or psychosocial)~* Females: could not be pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetylcysteine (Type: EXPERIMENTAL): Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
- Placebo (Type: PLACEBO_COMPARATOR): Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
The identification of NTG was based on reproducible glaucomatous visual field defects, corresponding to typical ONH changes.~Unilateral or bilateral visual field loss (description as below) as determined by at least two consecutive automated static threshold perimetry tests.~One eye is randomly selected in the cases where both eyes are treated.~Inclusion criteria:~1. age ranging from 45 to 75 years~2. best-corrected visual acuity no worse than 20/30 Snellen equivalent~3. optic nerve head cupping (i.e., a vertical cup-to-disc ratio of more than 0.6) and/or notching of neuroretinal rim, and/or retinal nerve fiber defects characteristic of glaucoma~4. visual field loss (i.e., a localized defect with at least three adjacent nonedge points depressed \>5 dB from the normal value, and a nucleus of at least one point depressed 10 dB from the normal value)~5. repeated measurements of untreated IOP, which documented values less than 22 mmHg~6. central corneal thickness ranging from 540 to 560 microns~7. open-angle confirmed by gonioscopy~Exclusion criteria:~1. active or chronic systemic diseases and/or concomitant assumption of any medication known to affect IOP, BP and/or HR~2. corneal abnormalities preventing reliable applanation tonometry~3. severe ocular trauma, ocular inflammation or infection, intraocular surgery or argon laser treatment or laser trabeculoplasty~4. myopic or other fundus changes preventing reliable optic disc evaluation,~5. visual field defects caused by nonglaucomatous disease~6. history of allergy to the ingredients of Cosopt or Xalatan eye drops

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
- Arm 2 (Type: ACTIVE_COMPARATOR): Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosis of atopic dermatitis for greater than (\>) 1 year~* Atopic dermatitis involvement of greater than or equal to (\>=) 10 percent (%) body surface area~* EASI score of \>= 12~* SCORAD of \>= 25~* IGA score of \>= 3~* Effective birth control in line with protocol details~Exclusion Criteria:~* History of anaphylaxis following any biologic therapy~* Hepatitis B, C or human immunodeficiency virus~* Pregnant or breastfeeding~* History of cancer~* Previous receipt of tralokinumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
- Tralokinumab Dose 1 (Type: EXPERIMENTAL): Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
- Tralokinumab Dose 2 (Type: EXPERIMENTAL): Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
- Tralokinumab Dose 3 (Type: EXPERIMENTAL): Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women must be at least 18 years of age at the time of screening~* Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization Patients with moderate to severe plaque psoriasis who are candidates for systemic therapy as defined at randomization by:~* PASI score of \>10~* Affected body surface area (BSA) \> 10%~* DLQI \>10~* Inadequate response, intolerance or contraindication to topical psoriasis treatment as documented in the patient's medical history or reported by the patient or determined by the investigator at screening.~Exclusion Criteria (abbreviated):~* Previous systemic treatment of plaque psoriasis or known contraindication for systemic therapy at baseline~* Ongoing use of other prohibited psoriasis and non-psoriasis treatment.~* Clinically important active infections or infestations, chronic, recurrent or latent infections or infestations~* Patients with severe liver diseases~* Patients with severe gastrointestinal diseases including but not limited to ventricular and duodenal ulcers~* Patients with severe kidney diseases or serum creatinine above 1 x ULN~* Patients with known hematological disease or lab abnormalities~* Pregnancy, breast feeding, or unwillingness/inability to use appropriate measures of contraception (if necessary)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
- Fumaric acid (initial and maintenance therapy) (Type: ACTIVE_COMPARATOR): Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for all patients:~* ≥ 18 years of age~* Able to comply with study and follow-up requirements~Inclusion Criteria for high risk patients:~* elected to undergo prophylactic salpingo-oophorectomy~* fertile patients must use effective non-hormonal contraception~* agreed to use a nonhormonal means of contraception before surgery~* serum bilirubin ≤ 1.0 x Upper Limit Normal (ULN), alkaline phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) ≤ 2.5 x ULN~* serum creatinine ≤ 1.5 x ULN~* granulocyte count ≥ 1500/μL~* platelet count ≥ 75,000/μL~* hemoglobin ≥ 9 g/dL~* adequate complete blood count~* At high risk for developing ovarian cancer, as defined by any of the following:~* Breast Cancer carried a BRCA1 or BRCA2 deleterious mutation, a Lynch syndrome mutation, and/or defined by a family history of: 1 first-degree relative with epithelial ovarian cancer, ≥1 first-degree female relative with breast cancer when ≤40 years old, ≥1 first-degree female relative with breast cancer when ≤50 years old, male relative with breast cancer, and/or family history of breast cancer or ovarian cancer.~Inclusion Criteria for low risk patients:~* planning to undergo oophorectomy for a medical indication~* did not fulfill criteria for high risk of developing ovarian cancer~Exclusion criteria:~* liver disease, current alcohol abuse, or cirrhosis~* pregnancy or lactation~* current use of hormone therapy~* active treatment for cancer~* recent, current, or planned participation in another experimental drug study~* breast cancer within the past 5 years~* significant traumatic injury within the past 6 months~* major surgery within the past 6 months~* any disease, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates the continued use of an investigational drug or that may render the patient at high risk from treatment complication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 83 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: ACTIVE_COMPARATOR): Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.
- High Risk Arm (Type: NO_INTERVENTION): High risk patients underwent risk-reducing salpingo-oophorectomy.
- Low Risk Arm (Type: NO_INTERVENTION): Low risk patients underwent salpingo-oophorectomy for a medical indication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Insulin-resistant PCOS (Arm: PCOS Affected Women)~* Irregular menstrual cycle (Arm: PCOS Affected Women)~* Hyperandrogenism (Arm: PCOS Affected Women)~* Regular menstrual cycles (Arm: Normal Controls)~* Normal hormonal levels (Arm: Normal Controls)~* Lack of hirsutism (Arm: Normal Controls)~* Acne-free (Arm: Normal Controls)~* Candidates are BMI-matched and screened for insulin resistance prior to inclusion. (Arm: Normal Controls)~Exclusion Criteria:~* Left handedness~* Acute medical illness~* Uncorrected thyroid disease~* Diabetes renal~* Cardiac or pulmonary insufficiency~* Active liver disease~* Neurological disease~* Current psychiatric illness~* Claustrophobia~* Contraindications to MRI~* Smoking~* Use of hormones~* Centrally acting or insulin sensitizing mediations~* Allergy to any opioid medication~* Substance abuse~* Pregnancy~* BMI \>35.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Normal Controls (Type: NO_INTERVENTION): Control subjects will have 5 visits (screening, oral glucose tolerance test (OGTT), neuropsychological testing, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) as they will receive no treatment and will not have repeat studies. The baseline values obtained from the control subjects will be compared to the baseline values acquired from the PCOS affected subjects.
- PCOS Affected Women-Metformin Treatment (Type: EXPERIMENTAL): Subjects with Polycystic Ovary Syndrome (PCOS) will be scheduled for 9 visits total: following the screening visit they will go through OGTT, neuro-psychological testing, fMRI and PET scan before and after 4 months of metformin use: 500mg tablets once daily with breakfast for 1 week, then increased to one tablet twice daily with breakfast \& lunch for 1 week, then increased to one tablet three times daily with breakfast, lunch \& dinner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.~At least 18 years of age~If female, and of child-bearing potential, is using an acceptable form of birth control~Negative urine pregnancy test at screening, if applicable~In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study~Exclusion Criteria:~Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.~Subjects who had previous significant gastrointestinal surgeries~Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on screening laboratory results, such as hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia, dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.~Subjects with a prior history of renal, liver or cardiac insufficiency~Subjects with impaired consciousness that predisposes them to pulmonary aspiration.~Subjects undergoing colonoscopy for foreign body removal and/or decompression.~Subjects who are pregnant or lactating, or intending to become pregnant during the study.~Subjects of childbearing potential who refuse a pregnancy test.~Subjects allergic to any preparation components.~Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.~Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.~Subjects who withdraw consent before completion of Visit 1 procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SUPREP Bowel Prep Kit (Type: EXPERIMENTAL): SUPREP Bowel Prep Kit
- FDA approved bowel preparation (Type: ACTIVE_COMPARATOR): FDA approved bowel preparation containing electrolytes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete